Incyte Announces Data from Phase 2b Study Evaluating Povorcitinib (INCB54707) in Patients with Extensive Nonsegmental Vitiligo

WILMINGTON, Del.–(BUSINESS WIRE)—- $INCY–Incyte Announces Data from Phase 2b Study Evaluating Povorcitinib (INCB54707) in Patients with Extensive Nonsegmental Vitiligo



Source link
#Incyte #Announces #Data #Phase #Study #Evaluating #Povorcitinib #INCB54707 #Patients #Extensive #Nonsegmental #Vitiligo